Citi Maintains on Intercept Pharmaceuticals
January 10, 2014 at 10:08 AM EST
In a report published Friday, Citi analyst Yaron Werber maintained a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT ), raising its price target from $60.00 to $400.00. According to the report, the new price target reflects a ~45 percent upside to yesterday's close. The increase is driven by the